Moreover, despite the fact that DEC augments chemotherapy responses in TP53mut AML, with a currently unknown underlying mechanism, these responses are not durable and do not significantly affect subclones bearing TP53 mutations [31]. This evidence concerns the gene TP53 and acute myeloid leukemia.